Literature DB >> 9929518

Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes.

M Bourrié1, V Meunier, Y Berger, G Fabre.   

Abstract

The oxidative metabolism of irbesartan, a new nonpeptide angiotensin II receptor antagonist, was investigated on 12 human fully characterized hepatic microsomes and purified cytochrome P-450 (CYP) isoforms. After incubation of microsomes with irbesartan and NADPH, four main hydroxy metabolites were formed, as confirmed by liquid chromatography-mass spectrometry analysis. Irbesartan oxidation follows Michaelis-Menten kinetics, consistent with the involvement of a single CYP isoform in these hydroxylation processes. Only a low interindividual variability (2-fold difference) was observed in drug oxidation, even in preparations lacking CYP2D6. Km and Vmax for irbesartan oxidation were 54 +/- 6.5 microM and 0.62 +/- 0.18 nmol/min/mg, respectively. Irbesartan oxidation correlated (r2 = 0. 769) with tolbutamide (CYP2C9 substrate) 4-methyl-hydroxylation. Oxidation of irbesartan was markedly inhibited by sulfaphenazole (CYP2C9 inhibitor), but not by any of several other CYP inhibitors. In the same manner, both tolbutamide and warfarin (CYP2C9 substrates), were competitive-type inhibitors of irbesartan oxidation with Ki values of 500 and 30 microM, respectively. Moreover, irbesartan was a competitive-type inhibitor of tolbutamide 4-methylhydroxylation (Ki = 317 microM). Nifedipine also potentially decreased irbesartan oxidation, whereas neither ketoconazole and triacetyloleandomycin (CYP3A inhibitors), nor diltiazem and verapamil, (CYP3A4 substrates), exhibited an inhibitory effect. Additional studies demonstrated that nifedipine was an inhibitor of irbesartan (Ki = 20 microM) and tolbutamide oxidation processes, whereas irbesartan had no effect at all on nifedipine dehydrogenation. Enzyme kinetics suggest that nifedipine is a noncompetitive-type inhibitor of CYP2C9-mediated catalytic activities. Finally, only microsomes containing recombinant human liver CYP2C9 were capable of oxidizing irbesartan. These results provide evidence that CYP2C9 plays a major role in irbesartan oxidation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9929518

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

Review 1.  Pharmacogenetics of target genes across the warfarin pharmacological pathway.

Authors:  Suman Lal; Srinivasa Rao Jada; Xiaoqiang Xiang; Wan-Teck Lim; Edmund J D Lee; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population.

Authors:  Xiumei Hong; Shanchun Zhang; Guangyun Mao; Shanqun Jiang; Yan Zhang; Yunxian Yu; Genfu Tang; Houxun Xing; Xiping Xu
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

Review 3.  Irbesartan: an updated review of its use in cardiovascular disorders.

Authors:  A Markham; C M Spencer; B Jarvis
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

Review 4.  Drug interactions with irbesartan.

Authors:  M R Marino; N N Vachharajani
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.

Authors:  Chang-Ik Choi; Mi-Jeong Kim; Eun-Kyung Chung; Hye-In Lee; Choon-Gon Jang; Jung-Woo Bae; Seok-Yong Lee
Journal:  Eur J Clin Pharmacol       Date:  2011-08-13       Impact factor: 2.953

Review 6.  Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives.

Authors:  Thomas Unger; Elena Kaschina
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 7.  Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

Authors:  Katherine F Croom; Monique P Curran; Karen L Goa; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Irbesartan: a review of its use in hypertension and diabetic nephropathy.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.

Authors:  Anne-Charlotte Castellan; Michel Tod; François Gueyffier; Mélanie Audars; Fredéric Cambriels; Behrouz Kassaï; Patrice Nony
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

10.  Irbesartan/Hydrochlorothiazide : in moderate to severe hypertension.

Authors:  Jamie D Croxtall; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.